NLRP3 and rheumatoid arthritis: One study investigated the effect of combination therapy in RA and found that miR-26b and miR-20a inhibit glycogen synthase kinase-3 beta (GSK-β) and nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3), respectively, and negatively regulate the GSK-3β/NF-κB/NLRP3 pathway [103].